Sponsored by Purdue Pharma L.P.
This activity is not certified for credit.
Tuesday, September 6
In today’s age of instantly accessible information, misconceptions are formed at the speed of a tweet and just as quickly accepted as fact. This happens with many aspects of pain management—especially regarding opioids with abuse-deterrent properties (OADP). How does the FDA decide to give OADP labeling to an opioid? How can the prescriber tell which opioid analgesics are labelled as OADP and which aren’t? What legislation has been passed by which states for access to OADP? What percentage of the US population use opioid analgesics inappropriately? How do they obtain the prescription they prefer? The answers may surprise you. This program will help explore these questions and analyze the role of clinicians, industry, and government in reducing opioid misuse, abuse, and diversion in order to help you separate truth from myth.
No Preregistration Required
Ellen Battista, NP
J. David Haddox, DDS, MD